Recent Publications View all
- [Show abstract] [Hide abstract]
ABSTRACT: /st>To highlight the health-related quality of life scale scores for Saudi patients with different types of cancer, to get understanding and foundation for improvements. To suggest suitable plans for quality of life improvement based on study outcome. The role of oncology pharmacy will be stressed. /st>A cross-sectional descriptive study was conducted at a tertiary regional hospital using the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire. Attendees were patients diagnosed with any type of cancer and eligible for active anticancer treatment and/or palliative care. /st>Quality of life was evaluated for 87 participants. Most of patients were aged between 51 and 60 years; and 50% had active treatment with chemotherapy. Patients seemed to perform well with respect to average scores in both the symptoms and the functional health status scales. The mean score for the global quality of life scale was 47.2 ± 27.1, while the range of mean scores for the five function subscales was 59.0 ± 27.1 to 81.6 ± 13.8, indicating average level of general wellbeing with above average to high level of functional health status, while >50% of the patients met the operational criterion having less severe symptoms. Outpatients generally had somewhat higher scores as compared to hospitalized patients. /st>The general quality of life seemed satisfactory, but there is still need to improve care. Based on results from other studies, oncology pharmacists' roles are essential to improve quality of life through treatment counseling, follow-up on drug support therapy, stress on patient's education through specific programs, review and update the local guidelines, and conduct more research.Journal of Oncology Pharmacy Practice 09/2013; 20(4). DOI:10.1177/1078155213505255
Article: Disability in Saudi Arabia[Show abstract] [Hide abstract]
ABSTRACT: Disability is a complex, influential, dynamic, multidimensional challenge, and it can substantially limit major life activities of human beings and their ability to integrate/reintegrate into society. According to the World Health Organization reports almost 15% of the world's population lives with certain types of disability, of whom 2-4% experience substantial difficulties in functioning. In Saudi Arabia, very limited research has been conducted on the prevalence and incidence of disability, and most of this is on disabled children. There are several difficulties associated with conducting research on disability related issues in Saudi Arabia. Here, we review the current situation of disability, disability research, and rehabilitation in Saudi Arabia from the published literature.Saudi medical journal 05/2013; 34(5):453-60.
- [Show abstract] [Hide abstract]
ABSTRACT: To compare the sensitivity and specificity of Cepheid Gene Xpert, MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex (MTBC) and rifampin (RIF) resistance with conventional methods in respiratory and non-respiratory clinical specimens. We used a cross sectional design to evaluate a diagnostic test at the TB Section of the Division of Microbiology, Central Military Laboratory and Blood Bank, Prince Sultan Military Medical City, Riyadh, Kingdom of Saudi Arabia from October 2011 to January 2012. The detection of MTBC and RIF resistance using the Xpert MTB/RIF assay was assessed in 239 (172 respiratory, and 67 non respiratory) specimens received from 234 patients suspected of TB, and compared with conventional smear microscopy and culture methods. Out of the 239 specimens investigated, 62 (25.9%) were MTBC positive by culture, while 59 (24.6%) were positive by Xpert assay. Three samples showed false negative Xpert results. Compared with the culture, the Xpert assay achieved 95.4% (95% CI: 89-100%) sensitivity, and 100% (95% CI: 93.6-100%) specificity for respiratory samples, while the sensitivity for non-respiratory specimens was 94.4% (95% CI: 90.2-98.5), and the specificity for non-respiratory specimens was 100% (95% CI: 95.8-100%). Overall, a 95.2% (95% CI: 87.6-100) sensitivity, and 100% (95% CI: 92.4-100%) specificity, was observed for the Xpert MTB/RIF assay compared with conventional methods for MTBC detection. The gene Xpert MTB/RIF assay is a helpful tool for the detection of MTBC and RIF resistance in respiratory and non-respiratory clinical samples with a high sensitivity and specificity within 2 hours as compared with conventional methods, which took a much longer time.Saudi medical journal 10/2012; 33(10):1100-5.
Information provided on this web page is aggregated encyclopedic and bibliographical information relating to the named institution. Information provided is not approved by the institution itself. The institution’s logo (and/or other graphical identification, such as a coat of arms) is used only to identify the institution in a nominal way. Under certain jurisdictions it may be property of the institution.
Rg score distribution
No data available.